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ABSTRACT 
Background: ​In this brief report, we discuss enhancing access to hepatitis C treatment for uninsured patients in Southeast                  
Georgia. 
 
Methods: ​Through our screening program for hepatitis C virus (HCV) infections in a local safety net emergency department, the                   
Comprehensive AIDS Resources Emergency (CARE) Initiative studied the rates of linkage to care for newly diagnosed patients                 
with HCV and sought ways to improve linkage to care for those who did not have health insurance. 
 
Results: ​Our multidisciplinary team partnered with a local federally qualified health center (FQHC) and a wholesale laboratory                 
service to offer affordable care options, thus increasing the percent of uninsured patients who were linked to care for the treatment                     
of their chronic HCV infections. 
 
Conclusions: ​The creative use of non-invasive laboratory testing from non-traditional sources, and collaboration with              
pre-existing community partners is one way to make the care of chronic HCV infection attainable by uninsured and underinsured                   
patients 
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INTRODUCTION 
 
 
The Centers for Disease Control and Prevention (CDC),        
American Association for the Study of Liver Diseases        
(AASLD), and Infectious Diseases Society of America       
(IDSA) all recommend hepatitis C virus (HCV) screening at         
least once for individuals aged 18 and older (Schillie et al.,           
2020; AASLD and IDSA, 2019). A recent U.S. Preventive         
Services Task Force (USPSTF) update similarly      
recommends HCV testing for adults aged 18 to 79 (Chou et           
al., USPSTF 2019). This brief report describes how one of          
the Comprehensive AIDS Resources Emergency (CARE)      
Initiative’s screening programs enhanced access to care for        
uninsured patients who test positive for HCV. 
 
METHODS  
 
The data from this brief report come from the CARE          
Initiative (Okafor, 2019), a grant-funded screening program       
housed in the emergency department (ED) of a safety net          
hospital in the Savannah-Chatham County area. Safety net        
hospitals, as defined by the Institute of Medicine, commit to          
providing care to a substantial share of vulnerable patients         
regardless of their ability to pay (Popescu et al, 2019).          
Based on the most recent national data, Georgia had the          
sixth highest number of newly reported cases of confirmed         
chronic hepatitis C out of all states reporting data in 2017           
(CDC, 2019). 
 
The CARE Initiative’s HCV screening program began in        
February 2017, providing opt-out testing for ED patients        
born between 1945-1965 who were not previously tested;        
this was per the previous CDC guidelines (Chou et al.,          
2013) that recommended one-time testing only for adults        
born in this birth cohort and for at-risk individuals. Based on           
emerging evidence and the updated AASLD, IDSA, and        
USPSTF guidelines, we extended our screening program to        
include all adults aged 18 and older in March 2019. The           
initial screen is an HCV antibody test; positive antibody         
tests are followed by a confirmatory viral load test.         
Confirmed positive patients are counseled on the diagnosis        
by CARE linkage specialists and then linked to community         
providers. These linkage specialists continue with follow-up       
phone contact until an outpatient provider assumes care of         
the patient’s HCV infection. 
  
  
We obtained Institutional Review Board approval to study        
the demographics of all patients screened for HCV through         
the ED to implement quality improvement and       
population-level interventions to decrease the burden of       
HCV infection in the community. We measured the percent         
of patients who were successfully linked to care for the          
management of their HCV infection and studied linkage        
rates for various demographic variables, including insurance       
status. 
 
RESULTS 
 
Prior to the expansion of the program, approximately 5,000         
HCV tests were performed annually in the ED; once         
screening moved beyond the birth cohort to include all         
adults, we screened more than 15,000 patients in the         
subsequent year. The percentage of screened patients who        
tested positive (2.7%) did not change significantly after the         
age inclusion criteria moved beyond the 1945-1965 birth        
cohort; this is likely related to the fact that many older           
patients returned to the ED for various medical reasons after          
their one-time HCV test, and they were no longer eligible          
for screening. The linkage rate for all patients was 39% for           
the year leading up to the expansion beyond the birth cohort,           
and 36% in the subsequent year. 
 
Approximately 21% of those screened for HCV in the ED          
were uninsured or “self-pay” patients, and we discovered        
significant difficulty in linking these patients to care        
compared to our insured patients. A physician member of         
the CARE Initiative also worked part-time at a local         
federally qualified health center (FQHC) that cares for        
uninsured patients, and they agreed to see patients with         
HCV there. The CARE Initiative covers the cost of the HCV           
tests for diagnosis and confirmation; however, FQHC       
administrators had concerns about their ability to cover the         
more than $1,000 per patient cost of the subsequent lab          
testing—specifically the HCV genotype test [for the specific        
strain of the virus] and tests for liver cirrhosis—that are          
required for management after the initial diagnosis. Through        
online searches for wholesale laboratory services, the CARE        
program coordinator found a partner in January 2020 that         
provided an adjusted price of $300 for the subsequent labs. 
 
Nine uninsured patients have already been successfully       
linked as of the time of submission; considering our average          
of 85 uninsured new diagnoses annually, this trend is         
significant. In our city, there were previously no providers         
who would accept uninsured patients for management of        
hepatitis C, creating a significant health inequity. Our        
interdisciplinary team of physicians, linkage specialists,      
laboratory technicians, and clinic administrators created a       
partnership that can be replicated to provide care for these          
patients. 
 
 
 
 
 ​DISCUSSION/CONCLUSIONS  
 
Previous initiatives have demonstrated the     
cost-effectiveness and impact of large-scale screening      
programs for HCV in emergency departments and primary        
care settings (Assoumou et al, 2018; Hsieh et al., 2016). The           
management of our patients after diagnosis was highly        
variable and impacted by differences in insurance status and         
reimbursement. A wholesale lab company based in a        
different state provided affordable prices for the tests        
required to manage and care for our newly diagnosed,         
uninsured patients with HCV. The lab service interfaces        
with multiple vendors and couriers that the FQHC uses for          
processing of results, which is how we obtained the lowest          
possible price. 
 
Prior to our use of the wholesale laboratory service, we          
found only two providers in the county that would accept          
our uninsured patients diagnosed with HCV. Because of        
heavy patient loads for non-HCV related issues, one of these          
providers agreed to accept a maximum of two patients per          
month, and they had strict eligibility criteria for accepting         
patients with HCV—including complete sobriety from      
alcohol and current management of any psychiatric       
diagnoses. For uninsured patients that were eligible, the        
monthly maximum created a long wait-list. 
 
When we approached other providers in our area about         
managing uninsured patients with HCV at perhaps a        
reduced rate with upfront cash payments, we encountered        
non-financial barriers as well. One clinic mentioned the        
downsides of targeting “that patient population” and had        
concerns about becoming known as “the Hep C Clinic.” The          
FQHC that we ultimately partnered with is accustomed to         
caring for individuals of any income level and insurance         
status, as well as patients with psychiatric or substance         
abuse disorders. We found several uninsured patients       
willing to pay the adjusted wholesale price of $300, and in           
April 2020 we were able to decrease this cost further to           
$180 for most patients. Since the initial implementation has         
been cost neutral for the FQHC, they are exploring the          
development of additional HCV screening and management       
programs for some of their other community partners. 
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Disclaimer 
The CARE Initiative is funded by a FOCUS (Frontlines of          
Communities in the United States) grant through Gilead        
Sciences, Inc. FOCUS limits its support to testing and         
linkage to care. FOCUS does not support treatment and         
remains agnostic in partners' treatment decisions. 
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